Sequential tests of promise with discrete time-to-event data
Copyright © 2019 Elsevier Inc. All rights reserved..
We introduce a family of sequential test procedures in the context of a futility study design, or as we prefer to call it, a formal test of promise, suitable for use with time-to-event data. The procedures are motivated by an actual trial that was undertaken to test the promise of very early antiretroviral therapy to achieve viral remission in infants with perinatally-acquired HIV. Important gains in efficiency are illustrated in terms of early stopping and statistical power compared with other methods such as Simon's two-stage design with binary outcomes. We show how to calculate the operating characteristics of the proposed sequential tests of promise and provide optimal or near-optimal boundaries for small or medium size samples which provide the typical context for the tests under consideration. The design features discussed in this article are also of immediate pertinence to trials designed to test disease cures which may require treatment interruption and small numbers of participants.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:85 |
|---|---|
| Enthalten in: |
Contemporary clinical trials - 85(2019) vom: 01. Okt., Seite 105818 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Levin, Bruce [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ART cessation trials |
|---|
| Anmerkungen: |
Date Completed 21.10.2020 Date Revised 21.10.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cct.2019.105818 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM300548494 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM300548494 | ||
| 003 | DE-627 | ||
| 005 | 20231225102748.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cct.2019.105818 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1001.xml |
| 035 | |a (DE-627)NLM300548494 | ||
| 035 | |a (NLM)31445172 | ||
| 035 | |a (PII)S1551-7144(19)30533-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Levin, Bruce |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sequential tests of promise with discrete time-to-event data |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.10.2020 | ||
| 500 | |a Date Revised 21.10.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Inc. All rights reserved. | ||
| 520 | |a We introduce a family of sequential test procedures in the context of a futility study design, or as we prefer to call it, a formal test of promise, suitable for use with time-to-event data. The procedures are motivated by an actual trial that was undertaken to test the promise of very early antiretroviral therapy to achieve viral remission in infants with perinatally-acquired HIV. Important gains in efficiency are illustrated in terms of early stopping and statistical power compared with other methods such as Simon's two-stage design with binary outcomes. We show how to calculate the operating characteristics of the proposed sequential tests of promise and provide optimal or near-optimal boundaries for small or medium size samples which provide the typical context for the tests under consideration. The design features discussed in this article are also of immediate pertinence to trials designed to test disease cures which may require treatment interruption and small numbers of participants | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a ART cessation trials | |
| 650 | 4 | |a Futility design | |
| 650 | 4 | |a Non-superiority design | |
| 650 | 4 | |a Simon's two-stage design | |
| 650 | 4 | |a Survival data | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 700 | 1 | |a Kuhn, Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Leu, Cheng-Shiun |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Wei-Yann |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Contemporary clinical trials |d 2005 |g 85(2019) vom: 01. Okt., Seite 105818 |w (DE-627)NLM154869031 |x 1559-2030 |7 nnns |
| 773 | 1 | 8 | |g volume:85 |g year:2019 |g day:01 |g month:10 |g pages:105818 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cct.2019.105818 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 85 |j 2019 |b 01 |c 10 |h 105818 | ||